Bringing the fundamentals into focus…
Back to Spyre Therapeutics, Inc.
How Spyre Therapeutics, Inc. stacks up
SYRE · against 178 other Healthcare companies of similar size
Valuation
33/ 100
Near the bottom of its peers.
Ranked #140 of 179 · scores higher than 20% of peers
Bars: peers in each 10-point band of the valuation score15 peers with a valuation score of 30–39, including SYRE · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.9% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -2.4% vs peer median 0.0%
- EBITDA yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = SYRE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SYRE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 178 reported | -1.9% | 2.5% | 18% | 30% | |
| EBITDA yieldHigher is better · 177 reported | Not reported | 4.7% | — | — | 50% |
| Free cash flow yieldHigher is better · 106 reported | -2.4% | 1.8% | 22% | 20% | |
| Book yieldHigher is better · 178 reported | 10.9% | 19.8% | 26% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around SYRE| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 5 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 139 | 16.5B USD | 36 | 37 | |
| 140 | 6.1B USD | 33 | ||
| 140 | 4.5B USD | 33 | 33 | |
| 140 | 5.6B USD | 33 | 53 | |
| 140 | 8.8B USD | 33 | 50 | |
| 144 | 8.9B USD | 32 | 51 | |
| 145 | 4.7B USD | 30 | 42 | |
| 146 | 10.1B EUR (≈$11.1B) | 29 | ||
| 147 | 7.7B USD | 8 | 36 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score